The extremely rapid increase in prostate cancer survival reflects the increase in diagnosis and treatment of asymptomatic prostatic cancers as a result of increasingly widespread use of prostate-specific antigen (PSA) tests during the 1990s (Evans and Møller, 2003). The gene discussed is KLK3; the disease is prostate carcinoma.